Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate a new treatment strategy for advanced pancreatic
cancer disease by combining the new investigational medicinal product Atu027 with the
standard chemotherapeutic gemcitabine. This combination aims at enhancing gemcitabine´s
anti-tumor activity with Atu027.
The objectives of this clinical trial are to evaluate safety and activity of two Atu027
schedules in combination with standard gemcitabine treatment in patients with advanced or
metastatic pancreatic adenocarcinoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Silence Therapeutics GmbH
Collaborators:
FGK Clinical Research GmbH Granzer Regulatory Consulting & Services Granzer Regulatory Consulting and Services